Harnessing Nature’s Most Powerful Repertoire Generating System for use in T-cell Therapies: Fully Human TCRs and Fully Human Antibodies Specific for MHC/peptide Complexes.
Innovative Targeting Solutions has taken nature’s most powerful diversity generating system and has created a novel protein engineering technology capable of making and improving a wide variety of biologics. ITS has previously exploited V(D)J recombination to make first-in-class fully human antibodies and HCAbs (heavy chain only antibodies) to GPCRs. The company has now applied its HuTARG™ technology to isolate rare antibodies with TCR like properties (T-Mabs) that recognize specific MHC/peptide complexes. ITS has generated fully human T-Mabs to two different MHC/peptide complexes: anti-ESO peptide/MHC complex and anti-HIV peptide/MHC complex.
The HuTARG™ technology is the ideal tool for generating TCRs and CARTs and is a logical extension for ITS since in addition to B-cells the only other cell type that utilizes V(D)J reaction is T-cells. Because the HuTARG™ technology is a mammalian display platform, assays are conducted at the single cell level and billions of variants can be evaluated. Applying Next Generation Sequencing (NGS) to these large repertoires allows for rare antibodies with defined specificities to be identified.
Antibodies have historically been used to target secreted or membrane bound proteins which represent only a fraction of the proteins expressed in a cell, the ability to target MHC/peptide complexes opens many new targeting opportunities. We see these TCR like antibodies as not only having utility in T-cell therapies but also for ADCs and T-cell redirected applications.
Innovative Targeting Solutions Inc.